Compare PHVS & SAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHVS | SAH |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | 2020 | 1997 |
| Metric | PHVS | SAH |
|---|---|---|
| Price | $33.56 | $84.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | $41.82 | ★ $78.25 |
| AVG Volume (30 Days) | ★ 331.1K | 217.7K |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 2.07% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.79 |
| Revenue | N/A | ★ $9,951,630,000.00 |
| Revenue This Year | N/A | $4.61 |
| Revenue Next Year | N/A | $4.16 |
| P/E Ratio | ★ N/A | $46.21 |
| Revenue Growth | N/A | ★ 0.86 |
| 52 Week Low | $16.72 | $54.11 |
| 52 Week High | $35.33 | $89.38 |
| Indicator | PHVS | SAH |
|---|---|---|
| Relative Strength Index (RSI) | 61.64 | 57.68 |
| Support Level | $24.73 | $59.60 |
| Resistance Level | N/A | $84.61 |
| Average True Range (ATR) | 1.61 | 2.53 |
| MACD | 0.17 | -0.32 |
| Stochastic Oscillator | 64.53 | 78.01 |
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
Sonic Automotive is one of the largest auto dealership groups in the United States. The company has 111 franchised stores in 18 states, primarily in metropolitan areas in California, Texas, and the Southeast, plus 18 EchoPark used-vehicle stores in 10 states, 16 collision centers, and 14 powersports locations. The franchise stores derive revenue from new and used vehicles plus parts and collision repair, finance, insurance, and wholesale auctions. Luxury and import dealerships make up about 86% of franchise new-vehicle revenue, while Honda, BMW, Mercedes, and Toyota constitute about 56% of new-vehicle revenue. BMW is the largest brand at about 23%. 2025's revenue was $15.2 billion, with Texas and California comprising 51% of the total. EchoPark's portion was $2.1 billion.